share_log

RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $25 Price Target

RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $25 Price Target

RBC Capital重申apellis pharmaceuticals板块表现,维持25美元的目标股价
Benzinga ·  11/04 10:24  · 评级/大行评级

RBC Capital analyst Luca Issi reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform and maintains $25 price target.

RBC Capital分析师Luca Issi重申apellis pharmaceuticals(纳斯达克: APLS)的板块表现,并维持25美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发